1. Scrip
  2. >>Archive

Pfizer-Allergan Merger: The End Is Nigh

 
• By Mandy Jackson

The end of Pfizer Inc.'s $160bn merger with Allergan PLC was nearly official late on April 5 after the US Treasury Department issued new rules endorsed by President Barack Obama to prevent tax inversion deals, leading analysts and industry observers to declare the "PfizerGan" transaction unlikely.

The end of Pfizer Inc.'s $160bn merger with Allergan PLC was nearly official late on April 5 after the US Treasury Department issued new rules endorsed by President Barack Obama to prevent tax inversion deals, leading analysts and industry observers to declare the "PfizerGan" transaction unlikely.

Long after the US stock market closed on Tuesday, reports emerged saying that Pfizer would announce on Wednesday, April 6, that the big pharma and Allergan agreed to terminate their...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.